CVRx Plans Announcement of First Quarter Results
CVRx, Inc. (NASDAQ: CVRX), a leader in medical device innovation, is gearing up to unveil its financial and operating insights for the first quarter of 2025. The company's update will be shared after market hours, specifically on May 8, 2025. Following the release, CVRx will conduct a conference call at 4:30 PM Eastern Time to discuss the outcomes and future directions of the company.
Joining the Conference Call
Interested parties can participate in the conference call by dialing in approximately ten minutes before it begins. U.S. callers can reach the session by calling 1-800-445-7795, while international attendees can connect through 1-785-424-1699. When prompted, the conference ID CVRXQ125 will provide access to the discussion.
Experience the Webcast
A live webcast of this important investor event will be accessible on the investor relations page of CVRx's official website. This offers a convenient option for stakeholders and interested viewers to stay informed about the company's progress and upcoming projects.
What Sets CVRx Apart
CVRx specializes in developing, manufacturing, and marketing groundbreaking neuromodulation technologies tailored for patients battling cardiovascular diseases. Its flagship product, Barostim™, has made significant waves in the medical community. This innovative device, which received FDA approval, utilizes neuromodulation to alleviate heart failure symptoms. Barostim functions by delivering electrical signals to baroreceptors situated in the carotid artery's wall, effectively restoring autonomic balance within the nervous system.
Regulatory Approvals and Achievements
The Barostim device's remarkable achievements include obtaining the FDA Breakthrough Device designation and receiving authorization for use in heart failure patients across the U.S. Additionally, it has secured the CE Mark in the European Economic Area for treating both heart failure and resistant hypertension, marking significant progress in the field of cardiovascular treatment.
Contact Information for Investors and Media
For anything related to investor inquiries, Mark Klausner and Mike Vallie from ICR Westwicke are available to provide assistance. They can be reached at 443-213-0501 or via email. Media inquiries can be directed to Emily Meyers at CVRx, who can be contacted through 763-416-2853. This open line of communication ensures that investors, media, and interested parties can easily acquire the information they need.
Frequently Asked Questions
When will CVRx announce its first quarter 2025 results?
CVRx plans to release its financial results for the first quarter of 2025 on May 8, 2025.
How can I join the conference call hosted by CVRx?
To join the conference call, dial 1-800-445-7795 for U.S. callers or 1-785-424-1699 for international callers about ten minutes before the call starts.
What product does CVRx specialize in?
CVRx focuses on developing neuromodulation devices, with Barostim™ being their leading product for treating heart failure symptoms.
Does Barostim have FDA approval?
Yes, Barostim is approved by the FDA for patients experiencing heart failure and has also received CE Mark designation.
Who can I contact for more information about CVRx?
You can contact the investor relations team at ICR Westwicke or reach out to Emily Meyers for media inquiries for detailed information.
